Amneal Pharmaceuticals

Metsera partners with Amneal for weight loss therapy MET-097 development. Roivant Sciences gains rights to develop mosliciguat. Candid Therapeutics, led by Ken Song, focuses on autoimmune treatments. Quotient Therapeutics targets disease-related genes. Navigator Medicine advances NAV-240. Tome Biosciences faces uncertainty despite funding.

Metsera's MET-097i, a subcutaneous GLP-1 therapy, showed strong weight reduction (11.3% average) and a favorable tolerability profile in Phase IIa trials. With no plateau effect detected, potential for greater weight loss exists. The drug's ultra-long-acting profile supports monthly dosing. Metsera plans further studies and Phase III trials pending success.

Metsera's MET-097i, a subcutaneous GLP-1 therapy, showed strong weight reduction and a good tolerability profile in Phase IIa trials, with patients losing 11.3% body weight on average. The drug's ultra-long-acting profile supports potential monthly dosing. Metsera plans further studies and Phase III trials if successful.

The Federal Circuit U.S. Court of Appeals upheld a decision requiring Teva Pharmaceuticals to remove asthma inhaler patents from the FDA’s Orange Book, facilitating generic drug competition. The FTC supported this, highlighting the importance of removing improper patents to ensure affordable medication availability.

Metformin, primarily used for type 2 diabetes and polycystic ovary syndrome, is well-tolerated but can cause gastrointestinal issues. It lowers glucose production, increases insulin sensitivity, and reduces appetite. Despite its benefits, it's contraindicated in severe kidney disease due to lactic acidosis risk. It's widely prescribed, with ongoing research into its broader health impacts.

In 2024, *NeurologyLive*® produced 25 series on neurology, featuring experts discussing treatments for disorders like MS, SMA, myasthenia gravis, Alzheimer’s, narcolepsy, Parkinson’s, and pediatric epilepsy, emphasizing personalized care and emerging therapies.

2024's top psychiatry news includes FDA approvals like xanomeline/trospium chloride for schizophrenia and over-the-counter naloxone for opioid overdose. MDMA-assisted therapy for PTSD faced FDA rejection, while MM120 gained breakthrough status for anxiety. These developments highlight psychiatry's evolving landscape.

The U.S. OTC drugs market, valued at USD 23.83 billion in 2024, is projected to reach USD 41.72 billion by 2033, growing at a CAGR of 6.42%. Growth is driven by disease prevalence, self-medication trends, and regulatory approvals. Key segments include cough & cold products, tablets, oral administration, and drug stores & retail pharmacies.

In 2024, the FDA approved several therapies for neurological diseases, including treatments for CIDP, DMD, NMOSD, and Alzheimer's, offering new options and formulations to patients and clinicians.

FDA approved Hikma Pharmaceuticals USA’s generic liraglutide injection, referencing Novo Nordisk’s Victoza, for type 2 diabetes treatment. Amid a drug shortage, FDA prioritizes generic-drug applications to improve access. Liraglutide mimics GLP-1 effects, aiding blood sugar control. FDA’s efforts aim to enhance generic competition and patient access to complex drugs.